Skip to main content

La Marató awards six projects that involve IRB Barcelona

31 Oct 19

Images

Participants

Image
Research Associate
Tel.+34 93 40 34805

Contact

Image
Communication Officer
Tel.+34 93 40 37255

The foundation will be funding 43 cancer research projects.

Yesterday the Fundació La Marató de TV3 announced the 43 research projects that will receive funding from the €15 M raised in that last telethon, which was devoted to cancer. Six projects involving the participation of the Institute for Research in Biomedicine (IRB Barcelona) are among those selected for funding.

Thanks to the record amount collected in La Marató 2018, the investment in research this year is the largest ever awarded in the history of the organisation. The awards were announced yesterday in an act chaired by the Councillors of the Presidency and Health Meritxell Budó y Alba Vergés in the auditorium of the Academy of Medical and Health Science of Catalonia and the Balearic Islands.

 

IRB Barcelona researchers Eduard BatlleRaúl MéndezSalvador Aznar BenitahRoger GomisMaría Macías and Meritxell Teixidó are among the recipients of these awards.

 

How cancer evades our immune system

Coordinated by Eduard Batlle, ICREA researcher at IRB Barcelona and member of the CIBERONC network,and scientists Holger Heyn and Xavier Trepat, at CRG-CNAG and IBEC respectively, the study proposes to study how some tumours evade the immune system and specifically how they evade the action of T lymphocytes. “Understanding the functional bases underlying the exclusion of T lymphocytes from the centre of tumours will help not only to rationalize the use of immunotherapies but also foster new therapeutic strategies,” says Batlle.

 

Understanding the changes that take place in hepatic cells during cancer

Raúl Méndez, ICREA researcher at IRB Barcelona, and IDIBAPS scientist Mercedes Fernández coordinate the project entitled ‘Metabolic reprogramming in liver cancer is stimulated by obesity: functional mechanisms and therapeutic opportunities’. Méndez explains that “understanding the changes that occur in cells during cancer is key for identifying therapeutic targets and developing new treatments”. 

 

How diet affects cancer aggressiveness 

The project, which is coordinated by Salvador Aznar Benitah, ICREA researcher at IRB Barcelona,and scientist Ivo Gut, at CRG-CNAG, seeks to unravel why certain fatty acids favour metastasis—the process through which cancer cells spread from the primary tumour to other tissues. “The project also aims to increase public understanding of the health risks posed by high-fat processed foods,” says Aznar Benitah.

 

New strategies to treat RH+ breast cancer

RH+ breast cancer accounts for 75% of breast cancer cases and it is one of the main causes of death from cancer. The project, which involves Roger Gomis, ICREA researcher at IRB Barcelona, and Aleix Prat and Eva González, scientists at IDIBAPS and  IDIBELL respectively, seeks to study the response of  RH+  breast cancer cells to CDK4/6 inhibitors—a recently approved drug—and to design new strategies to overcome resistance to this treatment. “In summary, the preclinical results of this study will allow the design of new clinical assays that will finally contribute to improving the treatment and the survival of patients with RH+ breast cancer,” explains Gomis.

 

A diagnostic tool for endometrial cancer and prediction of relapse and metastasis

Maria Macías, ICREA researcher at IRB Barcelona, and scientists Virtudes Céspedes and Dr. Ramon Rovira, at the Hospital de la Santa Creu i Sant Pau, propose to develop a diagnostic tool that allows them to determine the probability of relapse and metastasis in endometrial cancer. This tool includes the use of genetic information, follow-up of patient progress, and artificial intelligence algorithms. “By developing new diagnostic tools that are affordable for the public health system, we hope to improve the care of patients with endometrial cancer and also to reduce the number of patients who die from this disease,” says Macías.

 

Drugs to reach the brain 

The project coordinated by researchers Ángel Montero, at the Hospital Sant Joan de Déu, and Meritxell Teixidó,  at IRB Barcelona, is called ‘Inhibition of the PI3K/Akt pathway in pediatric high grade and diffuse intrinsic pontine gliomas (pHGG/DIPG)”.“In this project we will be using our shuttles, which are capable of crossing the blood-brain barrier, to fight against paediatric brain tumours,” says Teixidó.

 

More information La Marató

 

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).